344 related articles for article (PubMed ID: 16291010)
21. Combination therapy with statins and omega-3 fatty acids.
Nambi V; Ballantyne CM
Am J Cardiol; 2006 Aug; 98(4A):34i-38i. PubMed ID: 16919515
[TBL] [Abstract][Full Text] [Related]
22. Reshaping the dyslipidemia management paradigm.
Guthrie RM
Postgrad Med; 2003 Aug; 114(2 Suppl):7-13. PubMed ID: 19667634
[TBL] [Abstract][Full Text] [Related]
23. Expert perspective: reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering.
Jones PH
Am J Cardiol; 2008 Dec; 102(12A):41L-47L. PubMed ID: 19084089
[TBL] [Abstract][Full Text] [Related]
24. The facts behind niacin.
Hochholzer W; Berg DD; Giugliano RP
Ther Adv Cardiovasc Dis; 2011 Oct; 5(5):227-40. PubMed ID: 21893559
[TBL] [Abstract][Full Text] [Related]
25. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
Hausenloy DJ; Yellon DM
Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
[TBL] [Abstract][Full Text] [Related]
26. [Treatment of dyslipidemia in clinical practice].
Paragh G; Harangi M
Orv Hetil; 2006 Mar; 147(9):389-94. PubMed ID: 16619956
[TBL] [Abstract][Full Text] [Related]
27. High-density lipoprotein metabolism: potential therapeutic targets.
Davidson MH; Toth PP
Am J Cardiol; 2007 Dec; 100(11 A):n32-40. PubMed ID: 18047851
[TBL] [Abstract][Full Text] [Related]
28. Niacin's role in the statin era.
Brooks EL; Kuvin JT; Karas RH
Expert Opin Pharmacother; 2010 Oct; 11(14):2291-300. PubMed ID: 20569085
[TBL] [Abstract][Full Text] [Related]
29. [Diabetic dyslipoproteinemia: beyond LDL].
Merkel M
Dtsch Med Wochenschr; 2009 May; 134(20):1067-73. PubMed ID: 19421932
[TBL] [Abstract][Full Text] [Related]
30. Management of dyslipidemia in diabetes.
Solano MP; Goldberg RB
Cardiol Rev; 2006; 14(3):125-35. PubMed ID: 16628021
[TBL] [Abstract][Full Text] [Related]
31. Reducing residual risk for patients on statin therapy: the potential role of combination therapy.
Davidson MH
Am J Cardiol; 2005 Nov; 96(9A):3K-13K; discussion 34K-35K. PubMed ID: 16291008
[TBL] [Abstract][Full Text] [Related]
32. Novel targets that affect high-density lipoprotein metabolism: the next frontier.
Davidson MH; Rosenson RS
Am J Cardiol; 2009 Nov; 104(10 Suppl):52E-7E. PubMed ID: 19895945
[TBL] [Abstract][Full Text] [Related]
33. [Therapy of dyslipidemia in post-infarction: state of the art].
Borgia MC; Nardi M; Da Ros S; Castellano V
Clin Ter; 2007; 158(6):523-32. PubMed ID: 18265719
[TBL] [Abstract][Full Text] [Related]
34. Fixed-dose combination of extended-release niacin plus simvastatin for lipid disorders.
Vo AN; Kashyap ML
Expert Rev Cardiovasc Ther; 2008 Nov; 6(10):1303-10. PubMed ID: 19018682
[TBL] [Abstract][Full Text] [Related]
35. Combination therapy for the treatment of dyslipidemia.
Streja D
Curr Opin Investig Drugs; 2004 Mar; 5(3):306-12. PubMed ID: 15083597
[TBL] [Abstract][Full Text] [Related]
36. Managing dyslipidemia in chronic kidney disease.
Harper CR; Jacobson TA
J Am Coll Cardiol; 2008 Jun; 51(25):2375-84. PubMed ID: 18565393
[TBL] [Abstract][Full Text] [Related]
37. Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk.
Brown BG; Zhao XQ
Am J Cardiol; 2008 Apr; 101(8A):58B-62B. PubMed ID: 18375243
[TBL] [Abstract][Full Text] [Related]
38. Effect of lipid-lowering drug therapy on small-dense low-density lipoprotein.
Backes JM; Gibson CA
Ann Pharmacother; 2005 Mar; 39(3):523-6. PubMed ID: 15671087
[TBL] [Abstract][Full Text] [Related]
39. The potential role of HDL- and LDL-cholesterol modulation in atheromatous plaque development.
Chapman MJ
Curr Med Res Opin; 2005; 21 Suppl 6():S17-22. PubMed ID: 16138937
[TBL] [Abstract][Full Text] [Related]
40. Management of hyperlipidemia: new LDL-C targets for persons at high-risk for cardiovascular events.
Balbisi EA
Med Sci Monit; 2006 Feb; 12(2):RA34-9. PubMed ID: 16449961
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
